227 related articles for article (PubMed ID: 32237253)
21. KRAS mutation-positive bronchial surface epithelium (BSE)-type lung adenocarcinoma with strong expression of TTF-1: a case providing a further insight as for the role of TTF-1 in the oncogenesis.
Takanashi Y; Tajima S; Hayakawa T; Neyatani H; Funai K
Int J Clin Exp Pathol; 2015; 8(11):15338-43. PubMed ID: 26823891
[TBL] [Abstract][Full Text] [Related]
22. The prognostic role of thyroid transcription factor-1 in lung adenocarcinoma.
Oktay E; Oflazoglu U; Varol Y; Tanriverdi O; Mermur N; Arda HU; Demir L; Keskin O; Ahmadli T; Somali I; Oztop I; Meydan N
J Cancer Res Ther; 2018 Dec; 14(Supplement):S1201-S1208. PubMed ID: 30539871
[TBL] [Abstract][Full Text] [Related]
23. Discriminating between Terminal- and Non-Terminal Respiratory Unit-Type Lung Adenocarcinoma Based on MicroRNA Profiles.
Kim MH; Cho JS; Kim Y; Lee CH; Lee MK; Shin DH
PLoS One; 2016; 11(8):e0160996. PubMed ID: 27575252
[TBL] [Abstract][Full Text] [Related]
24. Lung adenocarcinoma: Sustained subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status.
Sousa V; Rodrigues C; Silva M; Alarcão AM; Carvalho L
Rev Port Pneumol (2006); 2015; 21(3):113-25. PubMed ID: 25926253
[TBL] [Abstract][Full Text] [Related]
25. Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas.
Zhang Y; Wang R; Li Y; Pan Y; Hu H; Zhang Y; Li H; Shen L; Yu Y; Sun Y; Chen H
J Thorac Oncol; 2015 Oct; 10(10):1444-50. PubMed ID: 26200450
[TBL] [Abstract][Full Text] [Related]
26. Ribonucleic Acid In Situ Hybridization Is a More Sensitive Method Than Immunohistochemistry in Detection of Thyroid Transcription Factor 1 and Napsin A Expression in Lung Adenocarcinomas.
Shi J; Liu H; Ma XJ; Chen Z; He MX; Luo Y; Lin F
Arch Pathol Lab Med; 2016 Apr; 140(4):332-40. PubMed ID: 27028392
[TBL] [Abstract][Full Text] [Related]
27. Histological characteristics of lung adenocarcinoma with uncommon actionable alterations: special emphasis on MET exon 14 skipping alterations.
Hayashi T; Kohsaka S; Takamochi K; Kishikawa S; Ikarashi D; Sano K; Hara K; Onagi H; Suehara Y; Takahashi F; Saito T; Nakatsura T; Kitano S; Suzuki K; Yao T
Histopathology; 2021 Jun; 78(7):987-999. PubMed ID: 33249657
[TBL] [Abstract][Full Text] [Related]
28. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma.
Yatabe Y; Kosaka T; Takahashi T; Mitsudomi T
Am J Surg Pathol; 2005 May; 29(5):633-9. PubMed ID: 15832087
[TBL] [Abstract][Full Text] [Related]
29. Specific expression of MUC21 in micropapillary elements of lung adenocarcinomas - Implications for the progression of EGFR-mutated lung adenocarcinomas.
Matsumura M; Okudela K; Nakashima Y; Mitsui H; Denda-Nagai K; Suzuki T; Arai H; Umeda S; Tateishi Y; Koike C; Kataoka T; Irimura T; Ohashi K
PLoS One; 2019; 14(4):e0215237. PubMed ID: 30973916
[TBL] [Abstract][Full Text] [Related]
30. Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations.
Park JY; Jang SH; Kim HI; Kim JH; Park S; Hwang YI; Jung KS; Seo J; Lee CY; Ko Y; Park YB
BMC Cancer; 2019 Jun; 19(1):574. PubMed ID: 31196060
[TBL] [Abstract][Full Text] [Related]
31. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
Chen LF; Chen XY; Yu XB
Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
[TBL] [Abstract][Full Text] [Related]
32. Lung Adenocarcinoma With MUC4 Expression Is Associated With Smoking Status, HER2 Protein Expression, and Poor Prognosis: Clinicopathologic Analysis of 338 Cases.
Rokutan-Kurata M; Yoshizawa A; Sumiyoshi S; Sonobe M; Menju T; Momose M; Koyama M; Shigeto S; Fujimoto M; Zhang M; Morita S; Date H; Haga H
Clin Lung Cancer; 2017 Jul; 18(4):e273-e281. PubMed ID: 28065467
[TBL] [Abstract][Full Text] [Related]
33. Gastric-type gene expression and phenotype in non-terminal respiratory unit type adenocarcinoma of the lung with invasive mucinous adenocarcinoma morphology.
Koh MJ; Shin DH; Lee SJ; Hwang CS; Lee HJ; Kim A; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY
Histopathology; 2020 May; 76(6):898-905. PubMed ID: 31985086
[TBL] [Abstract][Full Text] [Related]
34. LKB1 loss by alteration of the NKX2-1/p53 pathway promotes tumor malignancy and predicts poor survival and relapse in lung adenocarcinomas.
Tsai LH; Chen PM; Cheng YW; Chen CY; Sheu GT; Wu TC; Lee H
Oncogene; 2014 Jul; 33(29):3851-60. PubMed ID: 23995788
[TBL] [Abstract][Full Text] [Related]
35. Absence of thyroid transcription factor-1 expression is associated with poor survival in patients with advanced pulmonary adenocarcinoma treated with pemetrexed-based chemotherapy.
Doherty MK; O'Connor E; Hannon D; O'Reilly A; Yen D; Redmond M; Grogan LM; Hennessy BT; Breathnach OS; Morris PG
Ir J Med Sci; 2019 Feb; 188(1):69-74. PubMed ID: 29948461
[TBL] [Abstract][Full Text] [Related]
36. TTF-1 expression in pulmonary adenocarcinomas.
Yatabe Y; Mitsudomi T; Takahashi T
Am J Surg Pathol; 2002 Jun; 26(6):767-73. PubMed ID: 12023581
[TBL] [Abstract][Full Text] [Related]
37. Inverse correlation between galectin-4 and TTF-1 in lung adenocarcinoma.
Hara K; Saito T; Hayashi T; Mitani K; Takamochi K; Oh S; Suzuki K; Yao T
Virchows Arch; 2017 Sep; 471(3):375-382. PubMed ID: 28725929
[TBL] [Abstract][Full Text] [Related]
38. HNF4α as a marker for invasive mucinous adenocarcinoma of the lung.
Sugano M; Nagasaka T; Sasaki E; Murakami Y; Hosoda W; Hida T; Mitsudomi T; Yatabe Y
Am J Surg Pathol; 2013 Feb; 37(2):211-8. PubMed ID: 23108025
[TBL] [Abstract][Full Text] [Related]
39. The nonsmokers' and smokers' pathways in lung adenocarcinoma: Histological progression and molecular bases.
Okudela K; Matsumura M; Arai H; Woo T
Cancer Sci; 2021 Sep; 112(9):3411-3418. PubMed ID: 34143937
[TBL] [Abstract][Full Text] [Related]
40. Pulmonary adenocarcinoma with high-grade fetal adenocarcinoma component has a poor prognosis, comparable to that of micropapillary adenocarcinoma.
Suzuki M; Nakatani Y; Ito H; Narimatsu H; Yamada K; Yoshioka E; Washimi K; Okubo Y; Kawachi K; Miyagi Y; Yokose T
Mod Pathol; 2018 Sep; 31(9):1404-1417. PubMed ID: 29785018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
